What is physiologically based pharmacokinetic (PBPK) modeling and why is it important in dose extrapolation?

• A. PBPK models simulate ADME using physiological compartments; important for translating external doses to internal doses across species, ages, and routes.
• B. PBPK models only predict solubility in water.
• C. PBPK models are used only for in vitro experiments.
• D. PBPK models are not relevant to dose extrapolation.

Answer: (A)

PBPK modeling represents the body as a set of interconnected physiological compartments with real-world properties like organ sizes, blood flows, and tissue composition. It combines these physiological details with drug-specific data—absorption, distribution, metabolism, and excretion rates—to predict how a chemical moves through and is processed by the body. From an external dose and a chosen exposure route, the model yields internal exposure metrics over time, such as tissue concentrations and overall exposure (AUC, peak levels).

This approach is especially powerful for dose extrapolation because it explicitly accounts for differences in anatomy and physiology across species, ages, and routes of exposure. It lets you ask questions like: given a certain animal dose, what would the internal exposure look like in humans? How would predictions change for a child versus an adult, or for oral versus inhaled exposure? By incorporating factors such as organ sizes, blood flow, enzyme maturation, and route-specific absorption, PBPK models enable more accurate translating of external doses to internal doses, supporting safer and more informed risk assessments.

The other ideas don’t capture this mechanistic, whole-body linkage between external dose and internal exposure. They might focus only on solubility, or only on in vitro data, or ignore dose extrapolation entirely, whereas PBPK explicitly connects physiology to how a chemical behaves in the body across different scenarios.